Marker Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 18, 2026

MRKR$0.99+10.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets


· · December 31, · · December 31,
	2025		2024
ASSETS
Current assets:
Cash and cash equivalents		$16,068,048		$19,192,440
Restricted cash		974,799		—
Prepaid expenses and deposits		658,750		483,717
Other receivables		1,369,400		2,346,703
Total current assets		19,070,997		22,022,860
Total assets		$19,070,997		$22,022,860

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$1,299,384		$1,753,954
Related party payable		—		1,710,500
Deferred revenue		974,799		—
Total current liabilities		2,274,183		3,464,454
Total liabilities		2,274,183		3,464,454

Stockholders’ equity:
Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at December 31, 2025 and 2024, respectively		—		—
Common stock, $0.001 par value, 30 million shares authorized, 16.7 million and 10.7 million shares issued and outstanding as of December 31, 2025 and 2024, respectively (see Note 7)		16,672		10,708
Additional paid-in capital		475,960,940		465,564,876
Accumulated deficit		(459,180,798)		(447,017,178)
Total stockholders’ equity		16,796,814		18,558,406
Total liabilities and stockholders’ equity		$19,070,997		$22,022,860

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.